Related Experiment Videos
Spironolactone-induced hyperchloremic acidosis in cirrhosis
Annals of Internal Medicine
|March 1, 1979
Summary
Spironolactone, an aldosterone antagonist, can cause reversible metabolic acidosis and increased potassium levels in patients with alcoholic cirrhosis. This side effect may occur alongside its intended benefits of managing fluid retention.
Area of Science:
- Nephrology
- Gastroenterology
- Pharmacology
Background:
- Alcoholic cirrhosis often leads to complications like fluid retention.
- Aldosterone antagonists, such as spironolactone, are used to manage fluid retention in cirrhotic patients.
- These medications can have side effects impacting electrolyte balance.
Purpose of the Study:
- To investigate the metabolic effects of spironolactone in patients with alcoholic cirrhosis.
- To identify potential complications associated with spironolactone therapy in this patient population.
Main Methods:
- Observational study involving six patients with alcoholic cirrhosis.
- Administration of spironolactone (100-200 mg/day) with monitoring of serum electrolytes and bicarbonate.
- Assessment of changes during spironolactone treatment and after its withdrawal.
Main Results:
- Spironolactone treatment led to a significant decrease in serum bicarbonate levels, indicating metabolic acidosis (18.2 to 10.9 meq/L).
- Serum potassium levels increased significantly during spironolactone therapy (3.7 to 5.0 meq/L).
- These adverse effects were reversible upon discontinuation of spironolactone.
Conclusions:
- Spironolactone can induce or exacerbate hyperchloremic metabolic acidosis in patients with alcoholic cirrhosis.
- While spironolactone helps manage fluid retention and prevent hypokalemia, metabolic acidosis is a significant potential complication.
- Careful monitoring of acid-base balance and electrolytes is crucial during spironolactone treatment for cirrhotic patients.